Oculis

News

Black and white close up image of an eye

Oculis takes second eye disease therapy into pivotal trials

Oculis is poised to start registration trials for privosegtor, its drug candidate for neuro-ophthalmic diseases, in the wake of positive phase 2 data.

News

Oculis SA and EBAC join to drive ophthalmology innovation

Oculis SA, a global biopharmaceutical company that develops treatments for saving sight and improving eye care with breakthrough innovations, is to combine with the European Biotech Acquisi

News

NHS "isn't delivering equitable care for rare diseases"

A Genetic Alliance UK report claims the NHS is failing to meet the needs of many of the 3.5 million people in the country who live with rare diseases.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks